David Aguiar-Bujanda

Dr. David Aguiar-Bujanda

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Antioxidants
Verified
Journal Article
Open access
PDF file
Bernardino ClavoBernardino Clavo
Bernardino Clavo
Francisco Rodríguez-EsparragónFrancisco Rodríguez-Esparragón
Francisco Rodríguez-Esparragón
DRDelvys Rodríguez-Abreu
Delvys Rodríguez-Abreu
Gregorio Martínez-SánchezGregorio Martínez-Sánchez
Gregorio Martínez-Sánchez
PLPedro Llontop
Pedro Llontop
NSNorberto Santana-Rodríguez
Norberto Santana-Rodríguez
(1) Background: Cancer is one of the leading causes of mortality worldwide. Radiotherapy and chemotherapy attempt to kill tumor cells by different mechanisms mediated by an intracellular increase of free radicals. However, free radicals can also increase in healthy cells and lead to oxidative stress, resulting in further damage to healthy tissues. Approaches to prevent or treat many of these side effects are limited. Ozone therapy can induce a controlled oxidative stress able to stimulate an adaptive antioxidant response in healthy tissue. This review describes the studies using ozone therapy to prevent and/or treat chemotherapy-induced toxicity, and how its effect is linked to a modification of free radicals and antioxidants. (2) Methods: This review encompasses a total of 13 peer-reviewed original articles (most of them with assessment of oxidative stress parameters) and some related works. It is mainly focused on four drugs: Cisplatin, Methotrexate, Doxorubicin, and Bleomycin. (3) Results: In experimental models and the few existing clinical studies, modulation of free radicals and antioxidants by ozone therapy was associated with decreased chemotherapy-induced toxicity. (4) Conclusions: The potential role of ozone therapy in the management of chemotherapy-induced toxicity merits further research. Randomized controlled trials are ongoing.

1 February 2004 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
DADavid Aguiar-Bujanda
David Aguiar-Bujanda
RPRoberto Pazo
Roberto Pazo
IDIgnacio Durán
Ignacio Durán
JTJosefa Terrasa
Josefa Terrasa
AAAntonio Arrivi
Antonio Arrivi
JRJulio Rifá
Julio Rifá

Verified
Journal Article
Open access
PDF file
Bernardino ClavoBernardino Clavo
Bernardino Clavo
Gregorio Martínez-SánchezGregorio Martínez-Sánchez
Gregorio Martínez-Sánchez
Francisco Rodríguez-EsparragónFrancisco Rodríguez-Esparragón
Francisco Rodríguez-Esparragón
DRDelvys Rodríguez-Abreu
Delvys Rodríguez-Abreu
SGSaray Galván
Saray Galván
Gustavo CallicoGustavo Callico
Gustavo Callico
(1) Background: Chemotherapy-induced peripheral neuropathy (CIPN) decreases the quality of life of patients and can lead to a dose reduction and/or the interruption of chemotherapy treatment, limiting its effectiveness. Potential pathophysiological mechanisms involved in the pathogenesis of CIPN include chronic oxidative stress and subsequent increase in free radicals and proinflammatory cytokines. Approaches for the treatment of CIPN are highly limited in their number and efficacy, although several antioxidant-based therapies have been tried. On the other hand, ozone therapy can induce an adaptive antioxidant and anti-inflammatory response, which could be potentially useful in the management of CIPN. (2) Methods: The aims of this works are: (a) to summarize the potential mechanisms that could induce CIPN by the most relevant drugs (platinum, taxanes, vinca alkaloids, and bortezomib), with particular focus on the role of oxidative stress; (b) to summarize the current situation of prophylactic and treatment approaches; (c) to describe the action mechanisms of ozone therapy to modify oxidative stress and inflammation with its potential repercussions for CIPN; (d) to describe related experimental and clinical reports with ozone therapy in chemo-induced neurologic symptoms and CIPN; and (e) to show the main details about an ongoing focused clinical trial. (3) Results: A wide background relating to the mechanisms of action and a small number of experimental and clinical reports suggest that ozone therapy could be useful to prevent or improve CIPN. (4) Conclusions: Currently, there are no clinically relevant approaches for the prevention and treatment of stablished CIPN. The potential role of ozone therapy in this syndrome merits further research. Randomized controlled trials are ongoing.

2 November 2006 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
DADavid Aguiar-Bujanda
David Aguiar-Bujanda
USU. Bohn Sarmiento
U. Bohn Sarmiento
MSM.á. Cabrera Suárez
M.á. Cabrera Suárez
JMJ. Aguiar Morales
J. Aguiar Morales
Background: Bisphosphonates (BP) decrease the incidence of skeletal related events among cancer patients with bone metastases from solid tumors and multiple myeloma. Renal safety and osteonecrosis of the jaws (ONJ) are two major concerns of toxicity. Information about safety of using BP beyond 2 years is scarce. Materials and methods: Patients receiving zoledronic acid (ZA) at the time of the study were reviewed. Serum creatinine levels (SCL) were collected at three different moments: before the start of BP (baseline), at the time of analysis (final), and the highest SCL during the treatment (highest). Oral examination was carried out in every patient. Separated analysis was made for patients on BP for >2 years. Concomitant risk factors for both renal toxicity and ONJ were evaluated. Results: Sixty-seven patients were included. Median time of BP was 22 months, with 22 patients receiving BP for >2 years. Median baseline and final values of SCL were 0.71 mg/dl and 0.70 mg/dl, respectively (P = 0.121). Median highest SCL during treatment was 0.82 mg/dl (P 2 years (P = 0.085). ONJ was also diagnosed in six patients, four of them in the group of prolonged BP treatment. Conclusion: ZA showed to be safe with a low rate of reversible renal toxicity. Patients receiving BP should be monitored carefully for renal toxicity and ONJ, especially those with exposure to BP beyond 2 years.

1 February 2008 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
DADavid Aguiar-Bujanda
David Aguiar-Bujanda
A 54-year-old woman presented with slow-growing cervical lymph nodes, weight loss and disseminated skin rash in February 2006. Biopsies from skin and cervical node revealed angioimmnunoblastic T-cell lymphoma (AILT), stage IVB. She received chemotherapy with cyclophospamide, doxorubicin, vincristine and prednisone, with a transient improvement of the skin rash and cervical nodes, followed by progression after three cycles. Second line with etoposide, methylprednisolone, cytarabine and cisplatin was tried, and again a short response followed by a rapid progression was observed, together with an important decrease in performance status and pancytopenia. She then started weekly oral methotrexate (20 mg) and daily prednisone (15 mg). After 3 months on treatment with disease stabilization, progression in skin, lymph nodes and bone marrow was observed. Her clinical condition was poor, developing deep venous thrombosis, pancytopenia and fever. At this point, fourth-line chemotherapy or alentuzumab was felt not possible, and therapy with the monoclonal anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was started in September 2006 at a dose of 10 mg/kg every 14 days. After three doses, blood counts rose to normal values and her general condition improved. She maintained low-dose prednisone (5 mg daily) and then switched to 30 mg daily for 5 days after every bevacizumab administration. Quality of life and tolerance were excellent, with only arterial hypertension grade 3 requiring combination antihypertensive agents as relevant toxicity. A complete response with total disappearance of enlarged lymph nodes and bone marrow infiltration, assessed by bone marrow biopsy and computed tomography scan, was observed after 3 months of therapy, lasting for 10 months. However, in July 2007, a new disseminated relapse occurred and the patient died in a few weeks.

1 March 2007 in The Breast Journal
Verified
Journal Article
Open access
PDF file
DADavid Aguiar-Bujanda
David Aguiar-Bujanda
JVJosé Carlos Rivero Vera
José Carlos Rivero Vera
MSMiguel Ángel Cabrera Suárez
Miguel Ángel Cabrera Suárez
JMJosé Aguiar Morales
José Aguiar Morales
RCRémy Christol
Rémy Christol
YBYves Le Bouc
Yves Le Bouc
Nonislet cell tumor hypoglycemia (NICTH) is uncommon, and has been related to the production of insulin-like growth factor II or its high-molecular-weight precursor (big IGF-II) by the tumor. Cases of NICTH have been related to different tumors, mainly sarcomas. However, only three cases secondary to a phyllodes tumor of the breast (PTB) have been previously reported. We present the clinical course of a woman with a giant PTB, who developed an irreversible hypoglycemic coma secondary to big IGF-II production by the tumor. A brief review of the literature and possible mechanisms of this infrequent condition are also commented.